Author

R. J. Nibbs

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Research Focus:host-pathogen & immune response· 2 Organism:mouse· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Assay:proteomics· 1

Frequent Co-Authors

D. Kerrigan· 1 shared D. Somma· 1 shared F. Herrington· 1 shared G. Naylor· 1 shared K. R. Keeshan· 1 shared L. Julian· 1 shared M. F. Olson· 1 shared M. Mullin· 1 shared

Activity by Year

2018-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperImmunology

D. Kerrigan

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Immunogenic cell death in mice expressing caspase-resistant ROCK1 is not replicated by ROCK inhibitors

G. Naylor, L. Julian, S. Watson-Bryce, M. Mullin, R. J. Nibbs, M. F. Olson

This study shows that caspase-resistant ROCK1 in mice leads to more immunogenic cell death in liver damage and tumors, but ROCK inhibitors do not replicate this effect.

bioRxiv · Apr 14, 2022 · PreprintCancer Biology

The IκB-Protein BCL-3 Controls MAPK Activity by Promoting TPL-2 Degradation in the Nucleus.

P. E. Collins, D. Somma, D. Kerrigan, F. Herrington, K. R. Keeshan, R. J. Nibbs, R. J. Carmody

This study shows BCL-3 promotes TPL-2 degradation in the nucleus, reducing MAPK activity and increasing the threshold for TLR-induced inflammation.

bioRxiv · Jul 20, 2018Immunology